ReviewOncoimmunology2014
Trial watch: Dendritic cell-based anticancer therapy.
Review in Oncoimmunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 69 citations in OpenAlex.
- Advances inMolecular therapy. Nucleic acids · 2026Review
- Biomarker-driven neoadjuvant immunotherapy in triple-negative breast cancer: emerging therapeutic targets FOXP3 and WT1.Frontiers in immunology · 2026Review
- Article
- Optimizing tumor-associated antigen-stimulated autologous dendritic cell and cytokine-induced killer cell coculture to enhance cytotoxicity for cancer immunotherapy in manufacturing.BMC immunology · 2023Article
- Biomaterials Facilitating Dendritic Cell-Mediated Cancer Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Review
- Directly injected lentiviral vector-based T cell vaccine protects mice against acute and chronic viral infection.JCI insight · 2022Article
- Lactate from the tumor microenvironment - A key obstacle in NK cell-based immunotherapies.Frontiers in immunology · 2022Review
- Generation of GM-CSF-producing antigen-presenting cells that induce a cytotoxic T cell-mediated antitumor response.Oncoimmunology · 2020Article
- Necroptotic-susceptible dendritic cells exhibit enhanced antitumor activities in mice.Immunity, inflammation and disease · 2020Article
- Development and Optimization of a GMP-Compliant Manufacturing Process for a Personalized Tumor Lysate Dendritic Cell Vaccine.Vaccines · 2020Article
- Personalized neoantigen-pulsed dendritic cell vaccines show superior immunogenicity to neoantigen-adjuvant vaccines in mouse tumor models.Cancer immunology, immunotherapy : CII · 2020Article
- Article
- The immunostimulatory effects and pro-apoptotic activity of rhCNB against Lewis lung cancer is mediated by Toll-like receptor 4.Cancer medicine · 2019Article
- Personalized Dendritic Cell Vaccines-Recent Breakthroughs and Encouraging Clinical Results.Frontiers in immunology · 2019Review
- 3-Day monocyte-derived dendritic cells stimulated with a combination of OK432, TLR7/8 ligand, and prostaglandin ECancer immunology, immunotherapy : CII · 2018Article
- Immunogenic effects of chemotherapy-induced tumor cell death.Genes & diseases · 2018Review
- Effect of immune tolerance induced by immature dendritic cells and CTLA4-Ig on systemic lupus erythematosus: AnExperimental and therapeutic medicine · 2018Article
- Combination Immunotherapy: Taking Cancer Vaccines to the Next Level.Frontiers in immunology · 2018Review
- Targeting Autophagy in ALK-Associated Cancers.Cancers · 2017Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 6 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The use of patient-derived dendritic cells (DCs) as a means to elicit therapeutically relevant immune responses in cancer patients has been extensively investigated throughout the past decade. In this context, DCs are generally expanded, exposed to autologous tumor cell lysates or loaded with specific tumor-associated antigens (TAAs), and then reintroduced into patients, often in combination with one or more immunostimulatory agents. As an alternative, TAAs are targeted to DCs
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.